ANB-010, dose 3 for hemophilia a

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Jul 2023: Trial started, NCT06185335
  2. 29 Dec 2023: Trial registered, NCT06185335

The trials

NCT06185335: A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

State
Under way
Phase
Phase 1 and Phase 2
People
50 planned
Started
26 Jul 2023
Primary completion
Dec 2025
Arms
Cohort 3
Results
None posted
  1. 26 Jul 2023: Trial started
  2. 29 Dec 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.